# Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

> **NCT00151281** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** PEPC
- **DRUG:** Thalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00151281
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2009-12
- **Final completion:** 2011-04-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00151281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00151281, "Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00151281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*